|
|
| |
|
Corporate overview
|
Medicago is a publicly-traded biotechnology company focused on the development, production and commercialization of protein-based vaccines and biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants.
To face pandemic and seasonal vaccine supply challenges, Medicago has developed a proprietary transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants. This technology offers significant advantages of speed and cost over competitive egg-based and cell culture technologies. It can deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from the pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of the pandemic strikes and to supply large volumes of vaccine antigens to the world market including developing countries.
The Company is developing its own proprietary pipeline of influenza vaccines.
|
|
|
